The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Q1 2026 Management View CEO William Meury framed Q1 as execution toward a post-Jakafi portfolio, saying, "We're off to a strong start in 2026 with net sales up 20% year-over-year, driven by strong ...

FAIRFIELD -- Fairfield American Little League's players are so well schooled, they rarely make a mistake. And their baseball education is owed to three teachers who played the game at high levels -- ...

Allergan has already had an eventful 2016. Last month, the drugmaker's $160 billion megamerger with Pfizer was scrapped after the US Treasury released new rules governing so-called tax inversions that ...

Clinical stage biopharma firm Karuna Therapeutics has named Bill Meury president and CEO, a move effective on January 3. He succeeds Dr. Steve Paul, who is transitioning to chief scientific officer ...

In his first public appearance as Incyte’s CEO, Bill Meury outlined his priorities for the company, which include taking a “fresh look” at the business’ R&D, operating expenses and capital allocation.

RBC Capital Markets said investors may view Incyte’s CEO change as a potential prelude to strategic moves or M&A activity, citing new chief executive Bill Meury’s track record of leading companies ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min While he understands the company ...

Bill Meury, president and CEO of Karuna Therapeutics, speaks with WebMD Chief Medical Officer John Whyte, MD, about the differences in drug development in psychiatry and the importance of innovation.